Wednesday, 5 February 2020

Future Scope of Overactive Bladder Treatment Market is Witness to Grow High CAGR till 2023

Market Scenario:
Overactive bladder is a condition that occurs in various diseases such as Parkinson's disease, multiple sclerosis, stroke, and others. Rise in prevalence of these diseases and rapid increase in the global geriatric population are inducing high demand for effective treatment of overactive bladder, which in turn is propelling the growth of the global overactive bladder treatment market. Increased marketing activities, availability of affordable treatments and development of innovative treatment procedures are also fueling the growth of the global overactive bladder treatment market. However, low penetration of treatment options in the healthcare sector and lack of awareness among the population of the underdeveloped countries are restricting the expansion of the global overactive bladder treatment market analysis during the assessment period.
The global overactive bladder treatment market is expected to gain prominence over the forecast period (2018–2023). It is estimated that the global overactive bladder treatment market is expected to register a CAGR of ~ 3.1% during the forecast period of 2018–2023.
Despite the drivers, lack of awareness in developing countries and undesired systemic effects of some current treatment options may hinder the growth of the market during the assessment period.
Company Profiles    
  • Astellas Pharma Inc.
  • Pfizer, Inc.
  • Teva Pharmaceutical
  • Allergan, Plc. 
  • Mylan N.V. 
  • Endo International Plc 
  • Hisamitsu Pharmaceutical Co., Inc.
  • Sanofi S. A.
  • Aurobindo Pharma Limited 
  • Johnson & Johnson
  • Intas Pharmaceuticals Ltd. 
  • Apotex Inc. 
  • Macleods Pharmaceuticals Ltd. 
  • Medtronic PLC
  • Cogentix Medical, Inc.
  • Others
Segmentation
The global overactive bladder treatment market is segmented on the basis of pharmacotherapy, non-pharmacological treatment, and disease.
On the basis of pharmacotherapy, the market is classified into anticholinergics, Botox, mirabegron, neurostimulation, and others. Further, anticholinergics are classified into solifenacin, oxybutynin, fesoterodine, darifenacin, tolterodine, trospium, and others.
The global overactive bladder treatment market on the basis of non-pharmacological treatment is segmented into dietary and fluid modifications, behavioral therapy, pelvic floor muscle rehabilitation, and others.
On the basis of disease, the market is segmented into idiopathic overactive bladder and neurogenic overactive bladder. Further, the neurogenic overactive bladder is segmented into the overactive bladder in Parkinson’s disease, the overactive bladder in stroke, the overactive bladder in spinal cord injury, and overactive bladder in other disorders.
Geographically, the global overactive bladder treatment market has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The overactive bladder treatment market in the Americas is further segmented into North America and South America. North America is further classified as the US and Canada.
The overactive bladder treatment market in Europe is segmented into Western Europe and Eastern Europe. Western Europe is further classified as Germany, France, UK, Italy, Spain, and the rest of Western Europe.
The overactive bladder treatment market in Asia-Pacific is segmented into Japan, China, India, Republic of Korea, Australia, and the rest of Asia-Pacific.
The overactive bladder treatment market in the Middle East and Africa is segmented into the Middle East and Africa.
Regional Market Summary
The global overactive bladder treatment market consists of four regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East and Africa. North America is anticipated to dominate the market in the Americas owing to the increasing geriatric population, growing occurrences of OAB, and the availability of numerous healthcare coverage systems such as Medicare.
Europe is anticipated to hold the second position in the global overactive bladder treatment market. It is estimated that the market growth in this region is attributed to the rising incidences of OAB and availability of reimbursement for certain treatment options. For instance, the UK’s National Institutes for Health and Care Excellence (NICE) provides reimbursement for the Botox therapy.
The overactive bladder treatment market in Asia-Pacific consists of countries, namely, China, Japan, the Republic of Korea, India, Australia, and the rest of Asia-Pacific. The Asia-Pacific region is expected to be the fastest growing region owing to the growing prevalence of bladder overactivity, rising geriatric population, rising healthcare expenditure, and increasing awareness about overactive bladder condition.
The Middle East and Africa are likely to hold the least share in the global overactive bladder treatment market. In this region, the Middle East is expected to dominate owing to the rising healthcare expenditure and rising occurrences of neurological diseases, especially among the aged population.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Posted by at No comments:
Labels:

Optical Imaging Market – A market with high CAGR and return on investment by 2023

Market Scenario
Optical imaging has the ability to improve point of care in the healthcare setting since it provides improved screening and detection of disease. The global optimal imaging market is anticipated to attain a valuation of USD 1.92 Bn at a CAGR of 10% over the forecast period of 2018-2023, projects Market Research Future (MRFR) in an extensive study.
Some of the Top Key Players in Optical Imaging Market are Jude Medical, Inc., Carl Zeiss Meditec AG, Bioptigen, Inc., Canon Inc, Heidelberg Engineering, Inc., Topcon Corporation, Perkinelmer, Inc., Koninklijke Philips N.V. and Agfa-Gevaert N.V. etc.
Driven by critical healthcare needs, optimal imaging is gaining traction as a detector technology. Optimal imaging is a technique where cellular and molecular function in a living body is interrogated with the help of light and the special properties of photons to obtain detailed images of organs and tissues.
Optical imaging is a non-invasive technique in which light is used to interrogate cellular and molecular function in the living body by exploiting the special properties of photons. This market is mainly driven by rising demand for non-invasive procedures, harmful effects of radiation-based imaging, increase in research and development activities in the life sciences sector, and increasing application of optical imaging techniques in drug discovery processes and preclinical research, Moreover factors such as rising geriatric population which leads to increase in cardiovascular, neurological and ophthalmic disorders is also fueling the growth of this market.
However, factors such as stringent regulatory approval procedures high costs of instruments, scarcity of skilled operators, and insufficient reimbursements policies for optical imaging procedures restrict market growth.
Regional Market Summary
In terms of geography, Americas dominates the market for optical imaging owing to increasing prevalence of cardiovascular, neurological and ophthalmic disorders about rising geriatric population which is a major trigger factor for this disease. Additionally, factors such as increasing government initiatives and funding for research in medical devices sector, rising demand for accurate diagnosis, awareness about adverse effects of radiation imaging, ability to provide in-depth images of soft tissues and vascular systems and presence of pharmaceutical giants key players also propel the market growth in this region. For instance, according to National cancer institute, in 2016, around 1,685,210 new cases of cancer were diagnosed in the U.S. Thus, this huge patient pool is going to boost up the market growth during the forecast period.
Europe is the second largest market and holds a healthy place in global optical imaging market share due to major driving factors like availability of advanced treatment facilities, increasing healthcare expenditure, good healthcare infrastructure and flourishing medical device industry due to the presence of major market players. Additionally, knowledge about the benefits of optical imaging over radiation imaging and capability of inhabitants to afford the diagnostics is spurring the market growth.
Asia Pacific is expected to be the fastest growing market with most promising growth possibilities. According to a report published by the department of neurology in 2014, it is estimated that for the current population of 1.27 billion, approximately 30 million people suffer from neurological disorders in India. Thus, owing to the huge patient pool, a faster adaptation of healthcare technology, government initiatives to increase the healthcare quality, availability favorable insurance policies market growth will be accelerated during the forecast period.  Moreover, due to lower cost of clinical trials and research key players have been setting up their regional headquarters and manufacturing plants in Singapore, China, Japan, Korea, and Australia which make a positive growth curve in optical imaging market in future.
Segmentation
The global optical imaging market is segmented on the basis of products, techniques, therapeutic area, application, and end-user. Considering the type of product, the market is segmented into imaging systems, software, lenses, illumination systems, cameras and others. Imaging systems are further segmented into optical imaging systems and spectral imaging systems. On the basis of technique, the market is segmented into Optical Coherence Tomography (OCT), photoacoustic imaging, diffused optical tomography, hyperspectral imaging, near-infrared spectroscopy, and super-resolution microscopy.
On a therapeutic area basis, it is segmented into neurology, oncology, ophthalmology, dentistry, cardiology, dermatology, and others. On account of application, the market is segmented into pre-clinical and clinical research, pathological imaging and intraoperative imaging. According to the end-user, the market is segmented into diagnostic imaging centers, hospitals and clinics, research laboratories, and pharmaceutical &biotechnology companies. Based on region the market is segmented into Americas, Europe, Asia Pacific, and the Middle East and Africa. Americas region is segmented into North America and South America. Similarly, Europe is segmented into Western Europe and Eastern Europe.

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Future Scope of Transthyretin Amyloidosis (ATTR) Market is Witness to Grow High CAGR till 2023

Transthyretin (TTR) Amyloidosis Market Information: Disease (Transthyretin (TTR) Familial Amyloid Polyneuropathy), Gender (Male & Female), Treatment (Small Molecule Treatment), & End-User (Ambulatory Surgical Center, Clinics) – Global Forecast Till 2023                                                                                                                          
Market Scenario
The Transthyretin (TTR) amyloidosis market is expected to register a sturdy growth during the forecast period.  Transthyretin (TTR) amyloidosis is a medical condition characterized by the buildup of abnormal deposits of a protein called amyloid (amyloidosis) in a body's organs and tissues. It generally affects peripheral neuropathic or autonomic neuropathy system and cardiac system. The cardiac form of Transthyretin (TTR) amyloidosis puts patients at the risk of arrhythmia, cardiomegaly, and orthostatic hypertension. The global ATTR market is likely to exhibit a robust growth during the forecast period due to the probability of rising number of ATTR therapeutic drugs launches, increasing African-American population as they are genetically susceptible to amyloidosis, increasing healthcare awareness among people, and rising average income of individuals. However, the growth of this market can be hindered by stringent regulatory policies, the high cost of ATTR drugs, incorrect diagnosis of ATTR disorders and limitations of clinical trials. Lack of knowledge about this condition and unavailability of advanced diagnostic methods in the middle-income countries are the major challenges to the market.

Top Market Players
  • Alnylam Pharmaceuticals
  • Pfizer
  • Merck
  • Ionis Pharmaceuticals Inc.
  • Corino Therapeutics Inc
  • Arcturus Therapeutics
  • Proclara Bioscience
Market Segmentation                                                                                                                          
Based on region the market is segmented into Americas, Europe, Asia Pacific, and the Middle East and Africa. The American region is segmented into North America and South America. Similarly, Europe is segmented into Western Europe and Eastern Europe.
The global Transthyretin (TTR) amyloidosis market is segmented on the basis of disease type, treatment, gender, and end-user. Considering the type of disease, the market is segmented into Transthyretin (TTR) familial amyloid polyneuropathy, Transthyretin (TTR) familial amyloid cardiomyopathy, and others. On the basis of treatment, the market is segmented into small molecules treatment, RNAi therapy,  organ transplantation, and others. Small molecules treatment is further segmented into tafamidis and diflunisal. On gender basis, it is segmented into male and female. According to end-user, the market is segmented into hospitals and clinics, ambulatory surgical centers, and others.
Regional Market Summary
Transthyretin Amyloidosis (ATTR) Market trends and share analysis on Regional basis, Americas dominates the market for Transthyretin (TTR) amyloidosis owing to the increasing prevalence of amyloidosis among adults and older population and rising geriatric population which is a major trigger factor for this disease. For instance, according to a report published by ASCO Journal in 2016 around 4,000 people developed amyloidosis each year in the United States. Thus, this rising patient pool is going to boost up the market growth during the forecast period. Additionally, factors such as increasing government initiatives and funding for research, development in advanced medical treatment options, and rising use of technologically advanced medical diagnostic devices are likely to drive the market. The presence of pharmaceutical giants such as Pfizer, Merck, etc. also propels the market growth in this region.
Asia Pacific is expected to be the fastest growing market. According to a report published by the United Nations in 2015the number of older people aged 60 years or over in the world is predicted to grow by 56% between 2015 and 2030, out of which 66% of the older population would reside in the Asia Pacific region. This makes the region prone to Transthyretin (TTR) amyloidosis as chances of its prevalence increases with the increasing age. Owing to a huge patient pool, a faster adaptation of healthcare technology, government initiatives to increase the healthcare quality, and availability favorable insurance and reimbursement policies, the market growth will be accelerated during the forecast period.  Moreover, key players such as Pfizer, Merck, etc. have been setting up their regional headquarters and manufacturing plants in countries such as Singapore, China, Japan, Korea, and Australia. Thus, the growth curve of the Transthyretin (TTR) amyloidosis market will see a positive trend of growth.
Europe is the second largest market and holds a healthy global Transthyretin (TTR) amyloidosis market share. The European market is expected to exhibit robust growth during the forecast period due to major driving factors such as availability of advanced treatment facilities, increasing healthcare expenditure along with growing need for better healthcare infrastructure, and government initiatives of healthcare reform.  It is reported that in the U.K., around 60 new cases of Transthyretin (TTR) amyloidosis are reported annually, and the age-specific incidence rate of it is between 5.1 and 12.8 per million per year. Additionally, established medical device market and capability of inhabitants to afford diagnostics are aiding the market growth. However, the inefficacy of treatment and wrong diagnosis are hampering the market growth of this region.
The Middle East and Africa is expected to show the least growth in the market due to some major factors such as lack of awareness and limited access and availability of treatment facilities. In the Middle East, the United Arab Emirates and Saudi Arabia are the largest markets owing to the development of the healthcare industry and rising availability of specialty care centers. But the market might show a steady growth due to the genetical susceptibility of Africans for transthyretin amyloidosis and government initiatives to improve the quality of healthcare in this region.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Gene Panel Market Poised to Witness a Significant Growth by 2023

Global Gene Panel Market: Information by Product & Service (Test Kits and Testing Services), By Technique (Amplicon-Based Approach and Hybridization-Based Approach), Design (Predesigned Gene Panels and Customized Gene Panels), Application (Cancer Risk Assessment, Diagnosis, and Pharmacogenetics), End User (Hospitals & Clinics, Research Organizations & Academic Institutes), Region (Americas, Europe, Asia-Pacific, Middle East & Africa) - Forecast till 2025
Market Scenario
The increasing prevalence of chronic diseases such as cancer, genetic diseases, and rare diseases, increase in adoption of genetic testing, rising company initiatives, technological advancements, need for efficient prenatal diagnosis, and increasing health awareness are estimated to drive the market during the forecast period. However, factors such as expensive tests, inaccuracy in results, and security concerns of the genes are estimated to restrain the market growth during the forecast period.
Global Gene Panel Market size is expected to register a CAGR of 12.16% to reach USD 4,347.32 Million by 2025.
Segmentation
The global gene panel market is segmented on the basis of product and service, technique, design, application, and end-user. The gene panel market, by product and service, is segmented into test kits and testing services. The global gene panel market by technique is segmented into the amplicon-based approach and hybridization-based approach. The design segment is segmented into predesigned gene panels and customized gene panels. On the basis of application, the market is categorized into cancer risk assessment, pharmacogenetics, diagnosis of congenital disorders, and other applications. The cancer risk assessment segment is further sub-segmented into syndrome-specific gene panels, high-penetrance gene panels, high and moderate-penetrance gene panels, and comprehensive cancer risk panels. On the basis of end-user, the market is categorized into hospitals, diagnostic laboratories, research and academic institutes, and pharmaceutical and biotechnology companies.
Key players
Some of the key players for the global gene panel market are Thermo Fisher Scientific (US), F. Hoffmann-La Roche AG (Switzerland), Illumina, Inc., BGI (China), Agilent Technologies (US),  Integrated DNA Technologies (IDT) (US), Eurofins Scientific (US), QIAGEN (Germany), GENEWIZ, Novogene Corporation (China), Personalis (US), GATC Biotech AG (GATC Biotech) (Germany), ArcherDx (US), GeneDx., CENTOGENE AG, and others.
Regional Market Summary
The Americas dominates the global market for gene panel. The increase in the patient pool for chronic diseases, government initiatives for the development of cancer treatment, and presence of strong market players such as Thermo Fisher Scientific drive the market growth in this region. Europe (the U.K., Belgium, France, and the Netherlands) is second in the market owing to the increasing research and development activities for cancer and congenital diseases. Also, the high occurrence rate of cancer in Europe influences the market growth in Europe. According to WHO, there are 3.7 million cases of cancer in Europe every year. Furthermore, Germany is predicted to dominate the European market as there were 2, 24,089 number of deaths due to cancer in 2014. Also, technological advancements coupled with an early diagnosis of cancer is likely to drive market growth for gene panel in Germany. Asia Pacific is expected to observe growth for the global gene panel market owing to the growing prevalence of cancer and increasing health expenditure. The Middle East and Africa with the presence of low-income countries, low healthcare expenditures, and stringent government regulations accounted for the least market share.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Defibrillators Pads Market to Witness an Outstanding Growth by 2023

Defibrillators Pads Market: By Product (Manual External, Manual Internal), by Age Group (Pediatric, Adult Defibrillator Pads), by Distribution Channel (Online, Retail, Hospital Pharmacy), and by End-Users (Hospitals & Clinics) – Global Forecast Till 2023
Market Synopsis of Global Defibrillators Pads Market:
Key Players
Medtronic, Cardiac Science Corporation, Koninklijke Philips N.V., Boston Scientific Corporation, Stryker Corporation, Cardinal Health, Biotronik SE & Co. KG, Defibtech, LLC., and  Mindray Medical are Some of the key players in the Defibrillators pads market.
Market Scenario:
Defibrillation is a procedure that involves the delivery of an electric shock to the heart which causes depolarization of the heart muscles and re-establishes normal conduction of the heart’s electrical impulse. To increase the efficacy of automated defibrillator, pads are attached to them which directly touches victim’s chest and delivers a shock to them. The gel present in the pads acts as a bonding agent and helps the AED pads to adhere firmly to the victim’s skin thus, increasing its efficacy.
Defibrillators Pads Market size is expected to register a CAGR of 5% during the forecast period.
The global defibrillators pads market is majorly driven by the increasing number technical advanced devices, increasing number of regulatory approvals, rising geriatric population, abuse of alcohol, the high prevalence of cardiac diseases such as ventricular fibrillation, ventricular tachycardia, and cardiac arrhythmias, and growing penetration of key market players. Furthermore, the increasing awareness of healthcare, favorable reimbursement policies, increasing innovations in research and development of medical devices, as well as rising average income of individuals are fueling the market growth. However, factors such as high cost of defibrillators pads and complicated and costly surgical procedures involved in implantation defibrillators are likely to hamper the growth of the market. Lack of proper healthcare infrastructure, as well as awareness regarding diseases such as cardiac arrhythmia and tachycardia in middle-income countries, are major challenges to the market growth.
Market Segmentation:
The global defibrillators pads market is segmented on the basis of product, age group, distribution channel, and end-user. According to products, the market is segmented into manual external, manual internal, automatic external, and others
Considering the age group, the market is segmented into pediatric defibrillator pads and adult defibrillator pads.
According to the distribution channel, the market is segmented into online pharmacy, retail pharmacy, hospital pharmacy, and others.
On account of end-user, the market is segmented into pre-hospital services, hospitals & clinics, alternate care facilities, public access market, and home healthcare services market.
Based on region the market is segmented into Americas, Europe, Asia Pacific, and the Middle East and Africa. Americas region is segmented into North America and South America. Similarly, Europe is segmented into Western Europe and Eastern Europe.
Regional Analysis:
Americas is the global leader for defibrillators pads market owing to increasing prevalence of cardiovascular diseases among adults and older population and rising more elderly population which increases the vulnerability to hypertension and obesity issues which are indirect causes of heart disease.  Additionally, factors such as increasing government initiatives and funding for research, development in advanced medical treatment options, and rising demand for technologically advanced treatment are likely to enhance the growth of defibrillators pads market in the American region. For instance, according to American Heart Association, in 2014, around 31% of the deaths in the U.S. were due to cardiovascular disorders. Similarly, according to stats presented in reports published by the Centers for Disease Control and Prevention,  heart disease is the most common cause of death and accounted for the death of about 366,000 people in 2015. This growing rate of cardiovascular disorders is expected to have a direct effect on the growth of the defibrillators pads market as it finds whole and sole application in cardiovascular disorders. 
Europe is the second largest market and holds a healthy share in the global defibrillators pads market. The European market is expected to grow at a sturdy growth rate during the forecast period due to major driving factors like availability of advanced treatment facilities, increasing healthcare expenditure along with growing need for better healthcare infrastructure and government initiatives of healthcare reform. For instance, according to 2017 statistics presented by the European Society of Cardiology, there were more than 6 million reported new cases of cardiovascular diseases in the European Union and more than 11 million in Europe as a whole. Additionally, every year 15% of deaths in Europe occur due to cardiovascular diseases. Hence cardiovascular disease being one of the major concern in Europe contributes significantly to the market growth of this region. Additionally, Europe spent around 210 Euros in 2015 for treatment of cardiovascular disorders. This rising healthcare expenditure due to cardiovascular disorders is expected to have a positive impact on the defibrillators pads market. Developed countries such as the U.S. and the U.K. are making it compulsory for certain sports arenas, schools, government facilities, and institutes to store and maintain Automated External Defibrillators (AEDs), as unavailability of defibrillators is the most common cause of sudden cardiac arrest.
The Middle East & Africa is expected to show the least growth in the market due to some major factors such as lack of awareness, limited access and availability of treatment facilities. In the Middle East, United Arab Emirates is the largest market share owing to the development of healthcare industry and rising availability of specialty care centers.
Asia Pacific is expected to be the fastest growing market. According to report published by the United Nations in 2015; between 2015 and 2030, the number of older persons aged 60 years or over in the world is predicted to grow by 56 %, out of which 66% of the older population would reside in Asia-Pacific regions. This makes the region prone to metabolic disorders that would further aid the chances of cardiovascular diseases. Owing to the huge patient pool, a faster adaptation of healthcare technology, government initiatives to increase the healthcare quality, favorable insurance and reimbursement policies, and key players such as Boston Scientific Corporation and Medtronic have been setting up their regional headquarters and manufacturing plants in Singapore, China, Japan, Korea, and Australia. This is accelerating the growth of the defibrillators pads market. Moreover, raising adaption of western culture has led to increasing sedentary lifestyle due to work culture, addiction to alcohol and smoking, consumption of fast foods which are the indirect causes of cardiovascular diseases and rise in the standard of living in the region also contributes to defibrillators pads market growth. However, on the other hand, factor such as lack of skilled healthcare professionals may slow down the market growth during the forecast period. For instance, according to the Global Burden of Disease Report in 2016, heart diseases is expected to lead to 1.7 million deaths in India. This rising prevalence of heart diseases is expected to propel the growth of the market.
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Coronary Stent Market | Worldwide Top key Players Profile Analysis | Forecast till 2023

Synopsis of the Global Coronary Stent Market
The global coronary stents market is projected to touch USD 9,382.63 million at a stupendous 7.81% CAGR over the predicted years (2018-2023). Coronary stents are utilized in angioplasty for making cross-section of blood vessels wider. The stent will reduce the chest pain along with recovering survivability during acute myocardial infarction. Coronary stents are used for treating cardiac diseases namely coronary artery disease, angina pain and myocardial infarction.
There are many factors that is driving the growth of the coronary stents market share. Some of these factors as per the Market Research Future (MRFR) report include increasing prevalence of CAD (coronary artery disease, innovations in coronary stents, increase in research and development of coronary stems, untapped emerging countries offering new market opportunities, lifestyle change diseases, increasing geriatric population, profound increase in healthcare coverage, advanced medical technologies, development of ICT (information and communication technology) and increase in government investment. On the contrary, factors such as high expenditure of procedures related to coronary stents coupled with accessibility of substitutes for CAD treatment is likely to hinder the growth of the coronary stents market.
Market Segmentation
Market Research Future report offers an all-inclusive segmental analysis of the coronary stents market on the basis of products and end user.
Based on products, it is segmented into Bioresorbable Vascular Scaffolds, Bare Metal Stents and Drug Eluting Stents. Of these, drug eluting stent is expected to lead the market during the predicted years owing to its increasing acceptance in better patient compliance, angioplasty procedures in comparison to bare metal stents. The bioresorbable stents is expected to expand at the fastest pace.
Based on end users, the coronary stents market is segmented into specialty centers, ambulatory surgical centers, hospitals and clinics and others. Of these, hospitals and clinics will have the maximum market share during the predicted years. This will be followed by the ambulatory surgical centers which will expand at the fastest rate.
Regional Analysis
Based on region, the coronary stents market covers growth opportunities and latest trends across North America, Europe, Asia Pacific and Middle East and Africa. Of these, North America will have a lion’s share in the market due to increasing cases of cardiovascular diseases mainly coronary artery disease, arterial blockage, cardiac arrythmia to name a few. Availability of advanced treatment methods and better therapeutic approaches has affected the growth of the market in this region in a positive way. The other factors that is driving the growth of the coronary stents market here include high disposable income, increasing medical awareness among the people here and existence of leading medical device manufacturers in this region. The coronary stents market in Europe holds the second largest share owing to the increasing support by the government for device manufacturers. Also, expansion of the companies geographically has resulted in a broader reach of medical services and products that has brought tremendous change with regards to acceptance as well as implementation of novel procedures and products. The coronary stents market in the APAC region experienced a huge growth due to the increasing development in the medical domain in the developing countries such as China and India. Besides, increasing medical device companies here, increasing research and development expenditure and increasing funding made by the government has resulted in its fastest growth. On the other hand, the coronary stents market in the Middle East and Africa is expected to have minimal growth opportunities.
Competitive Analysis
The coronary stents market is fragmented and highly competitive. The leading companies which have used strategies such as strategic alliances and mergers and acquisitions have gained a competitive advantage. Besides companies are highly focused to create products that are technologically advanced and deliver efficiency and greater accuracy.
Key Players
Leading players profiled in the coronary stents market include Terumo Corporation, Stentys SA, MicroPort Scientific Corporation, Meril Life Sciences, Medtronic plc, Elixir Medical Corporation, Cook Medical, R. Bard, Inc., Boston Scientific Corporation, Biotronik SE & Co. KG, and Abbott, B. Braun Melsungen AG.
Feb 2019- Biotronik has received approval from the FDA on its Ultrathin Orsiro Stent to treat coronary artery disease. This coronary stent will offer a novel treatment option to healthcare providers that will help in sealing the perforation to prevent blood leakage at the time of the procedure as well as avoid higher invasive surgical procedure or life-threatening complication.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Glioma Diagnosis and Treatment Market – Product Development is the best strategy for market position; Forecast till 2023

Market Scenario
A Glioma is a type of tumor that originates in the brain and is also known as a primary brain tumor. There are numerous types of gliomas which are entitled based on the origin of the cell type including oligodendrogliomas, astrocytoma, ependymomas, and glioblastoma. Nearly 33 percent of all brain tumors are gliomas. These originate in glial cells surrounding the neurons in the brain.
Global Glioma Diagnosis and Treatment market is expected to grow at a CAGR of approximately 10.1% during the forecast period, 2017–2023.
According to the American Brain Tumor Association, more than 79,000 new cases of primary brain tumors were diagnosed in 2017 with 24.7% of those being gliomas.
Brain tumors are one of the prominent causes of cancer among children and teenagers. Glioma is the most common type of brain tumor which accounts for approximately half of all the astrocytoma. The increasing occurrence of glioblastoma over the years is responsible for the growth of the glioma diagnosis and treatment market. The upcoming drug launches and developments in research are instrumental for the growth of the market. In addition, the current unmet need is expected to drive the gliomas industry over the forecast period. Changing financial demands and access to healthcare facilities are some of the factors that are constraining the market growth.
Astrocytoma is the most common types of glioma diagnosed worldwide, as more than 30% of all the diagnosed cases with brain tumors are astrocytoma. These types of tumors are not curable as they spread easily through normal brain tissue. The American Brain Tumor Association has evaluated that around 7% of all the primary brain tumors represent astrocytoma.
The expanding market for the treatment of brain cancer-associated symptoms, the increasing prevalence of brain cancer, and innovations in drug delivery to brain cancer cells are some of the key factors augmenting the demand in the global glioma diagnosis and treatment market. Furthermore, the introduction of novel therapies coupled with various organizations generating awareness and increasing geriatric population are factors driving the growth of the global glioma diagnosis and treatment market.
Key Players
Some of the key players in the global glioma diagnosis and treatment market are Thermo Fisher Scientific Inc. (U.S.), Emcure Pharmaceuticals Ltd. (India), Sigma-Aldrich Co. (U.S.), Pfizer Inc. (U.S.), Taj Pharmaceuticals Limited (India), Novartis International AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), GE Healthcare (U.S.), Siemens Healthineers (U.S.), Philips Healthcare (U.S.), Shimadzu Corporation (Japan), Toshiba Medical Systems Corporation (Japan), Merck & Co., Inc. (U.S.), F. Hoffmann-Le Roche AG (Switerland), Arbor Pharmaceuticals, LLC (U.S.), Sun Pharmaceutical Industries, Ltd. (India), Amneal Pharmaceuticals. LLC (U.S.), AstraZeneca (UK), Carestream Health (U.S.), Hitachi Medical Corporation (U.S.), and others.
Segmentation
Geographically, the Americas glioma diagnosis and treatment market is segmented into two major regions, namely, North America and South America.
North America accounted for the largest share of the global gliomas industry in 2016, and the trend is expected to continue over the projected period. Moreover, it is anticipated that about 80,000 new cases will be registered related to brain tumors in the year 2017 which includes 26,000 primary malignant brain tumors.
The Americas glioma diagnosis and treatment market is segmented on the basis of type, diagnosis, treatment, grade, location, and end-user.
Regional Analysis
The global glioma diagnosis and treatment market consist of four major regions, namely, the Americas, Europe, Asia Pacific, and the Middle East and Africa.
Growing medical tourism and prevalence of metastatic tumors that require surgical procedures are favoring the growth of the market in the Middle East and Africa. In addition, the development of drug delivery technologies, a combination of modern diagnostic techniques, and increasing awareness of various types of brain tumors are similarly supporting the growth of this market.
The Americas dominates the market owing to the key players domiciled in these regions coupled with the increasing incidences of brain tumor, rising awareness among people, and increasing healthcare expenditure. Brain tumor is the third most common types of cancer in adults in North America. According to the North American Brain Tumor Coalition over 44,500 people in the U.S. were diagnosed with a primary tumor in the brain in 2014. Thus, the increasing incidences of primary brain tumor support the growth of the malignant glioma treatment in North America.  
Asia Pacific is estimated to be the most lucrative market for gliomas due to the increasing occurrence of brain tumors in Asia Pacific countries such as China and others. The growth in the Asian market is fueled by the expanding healthcare infrastructure and presence of untapped market opportunities in this region. This region is considered as an emerging market owing to the increasing number of manufacturers coupled with the increasing market penetration.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:
Subscribe to: Posts (Atom)